Crossmark

An Economic Model to Assess the Cost Impact of Using Xpert Carba-R to Screen Carbapenemase-Producing Enterobacterales in Comparison with Standard of Care, in a National Health Service Setting

Crossref DOI link: https://doi.org/10.1007/s40121-025-01141-2

Published Online: 2025-04-19

Published Print: 2025-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Toumi, Mondher

Pulikottil-Jacob, Ruth

Watts, Karina

Odeyemi, Isaac

Butler, Karin
Funding

Funding for this research was provided by:

Cepheid
License Information

Text and Data Mining valid from 2025-04-19

Version of Record valid from 2025-04-19
More Information

Article History

Received: 20 January 2025

Accepted: 18 March 2025

First Online: 19 April 2025

Declarations

:

: The model used hypothetical data and does not contain any new studies with human participants or animals that were performed by any of the authors. Therefore, ethical approval and patient consent was not required for this study.

: Mondher Toumi has nothing to disclose. Ruth Pulikottil Jacob is an employee of Cepheid and Isaac Odeyemi was an employee of Cepheid at the time of writing. Karina Watts is an employee of YHEC and Karin Butler was an employee of YHEC at the time of writing. YHEC received consultancy fees from Cepheid.

Document is current

Any future updates will be listed below